Moreover, the 36-month beta value for VYNE is 1.23. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VYNE is 12.00M and currently, short sellers hold a 0.10% of that float. On April 04, 2024, VYNE’s average trading volume was 130.83K shares.
VYNE) stock’s latest price update
The stock price of VYNE Therapeutics Inc (NASDAQ: VYNE) has plunged by -6.45 when compared to previous closing price of 3.10, but the company has seen a -2.03% decline in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-03-19 that BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday, March 28, 2024.
VYNE’s Market Performance
VYNE Therapeutics Inc (VYNE) has seen a -2.03% fall in stock performance for the week, with a 28.89% gain in the past month and a 25.54% surge in the past quarter. The volatility ratio for the week is 6.96%, and the volatility levels for the past 30 days are at 9.71% for VYNE. The simple moving average for the last 20 days is 18.96% for VYNE stock, with a simple moving average of -11.94% for the last 200 days.
Analysts’ Opinion of VYNE
Many brokerage firms have already submitted their reports for VYNE stocks, with H.C. Wainwright repeating the rating for VYNE by listing it as a “Buy.” The predicted price for VYNE in the upcoming period, according to H.C. Wainwright is $7 based on the research report published on December 06, 2021 of the previous year 2021.
VYNE Trading at 30.44% from the 50-Day Moving Average
After a stumble in the market that brought VYNE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.78% of loss for the given period.
Volatility was left at 9.71%, however, over the last 30 days, the volatility rate increased by 6.96%, as shares surge +23.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +51.83% upper at present.
During the last 5 trading sessions, VYNE fell by -2.03%, which changed the moving average for the period of 200-days by -40.70% in comparison to the 20-day moving average, which settled at $2.47. In addition, VYNE Therapeutics Inc saw 24.46% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VYNE starting from LEPORE PATRICK G, who purchase 13,000 shares at the price of $3.91 back on Nov 15 ’23. After this action, LEPORE PATRICK G now owns 36,472 shares of VYNE Therapeutics Inc, valued at $50,778 using the latest closing price.
Stock Fundamentals for VYNE
Current profitability levels for the company are sitting at:
- -69.01 for the present operating margin
- 1.0 for the gross margin
The net margin for VYNE Therapeutics Inc stands at -67.1. The total capital return value is set at -0.32. Equity return is now at value -46.40, with -40.27 for asset returns.
Based on VYNE Therapeutics Inc (VYNE), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -118.42.
Currently, EBITDA for the company is -29.26 million with net debt to EBITDA at 1.04. When we switch over and look at the enterprise to sales, we see a ratio of 24.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.73.
Conclusion
To wrap up, the performance of VYNE Therapeutics Inc (VYNE) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
